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Abstract
Background: Opioid use is a significant problem in Alaska. Medication-assisted treatment for opioid use, including
buprenorphine, reduces withdrawal symptoms and the harm associated with opioid abuse. Understanding
consumers’ treatment-seeking process is important for addressing barriers to treatment, facilitating effective service
utilization, and informing policy.
Methods: To understand treatment-seeking behavior, we examined the attitudes, perceptions, and knowledge of
those who would benefit from the medication-assisted treatment (MAT) buprenorphine. Qualitative data from 2
focus groups (each including 4 participants) and 3 in-depth interviews with people who have used or considered
using buprenorphine in treatment for an opioid use disorder were analyzed using grounded theory and directed
content analysis approaches.
Results: Key findings suggest that individual (withdrawal process, individual motivation) and systemic (sociocultural,
political, societal values) factors frame the treatment seeking process. Participants’ progress on the treatment-
seeking road was affected by models of addiction and MAT, which related to facilitators and barriers encountered
in seeking treatment (e.g. support, resources, treatment structure). These factors shaped the longer-term road to
recovery, which was seen as on ongoing process.
Conclusions: The findings of this study suggest it is crucial for interventionists to take a contextual approach that
considers individual and systemic factors involved in opioid addiction, treatment, and recovery. This study
highlights ways policy makers and treatment providers can address the barriers consumers face in their treatment-
seeking process in order to increase treatment access.
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Background
Opioid use disorder involves continued misuse of opi-
oids despite recurrent problems occurring from use [1].
Due to the sizable incidences of nonmedical prescription
opioid initiation [2] and the harm associated with opioid
use including rising rates of overdose [3], there is alleged
to be a national opioid epidemic in the United States
[3–5]. Opioid misuse is also a noteworthy problem in
the state of Alaska, which consistently ranks in the top
ten states of the nation for illicit drug dependence [6].
Moreover, fatal drug overdose rates, the majority of
which include prescription drugs, increased by 55% be-
tween 1999 and 2010 in Alaska [7]. Particularly, in Al-
aska, the unmet treatment needs of citizens with drug
dependence have consistently registered above the na-
tional average [6]. Moreover, disparities have been found
in the services patients with co-occurring disorders re-
ceive, with those presenting for substance abuse, as op-
posed to mental health, treatment receiving less mental
health care despite having the same diagnoses [8]. The
rapidly rising rates of opioid misuse and the harm asso-
ciated with nonmedical prescription opioid use com-
pound the foregoing unmet needs of people who would
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Medication-assisted treatment (MAT) for opioid use
disorders, which use psychotropic drugs usually com-
bined with psychosocial treatment, has been empirically
indicated to reduce withdrawal symptoms, opioid abuse,
and the harm associated with opioid use [9–14]. For opi-
oid use disorders, MAT has frequently been associated
with the long-time “standard” replacement therapy:
methadone [9]. While methadone is an empirically vali-
dated medication that has illustrated efficacy in increas-
ing the viability of recovery by improving treatment
retention and reducing opioid use compared to non-
pharmacological alternatives in people with opioid de-
pendence [14], it may not be the treatment of choice for
some patients.
In 2002, the FDA approved buprenorphine as a new
MAT for opioid use disorders under the Drug Addiction
Treatment Act of 2000 [15]. Buprenorphine (Subutex®) and
the buprenorphine/naloxone combination (Suboxone®) are
established as effective, safe, and well-tolerated pharma-
ceutical treatments [10, 11] that increase patient engage-
ment and retention while reducing symptoms associated
with opioid use disorders [11, 13]. Compared with metha-
done (which must be dispensed at designated opioid treat-
ment programs), buprenorphine is prescribed by a qualified
general physician in an office-based setting and may in-
crease access to treatment [13]. Although the effectiveness
of buprenorphine is established, less is known about the
treatment-seeking behavior of those who would benefit
from buprenorphine treatment.
Project rationale
It is important to understand the attitudes and perceptions
of those who would benefit from treatment (now referred
to as consumers) as these factors influence the utilization
of services. Studies assessing treatment-seeking tendencies
for addictive disorders highlight barriers including stigma,
misattunement to patient needs (i.e., lack of gender-specific
services), and financial cost [16, 17]. While few qualitative
studies have explored what treatment consumers identify as
being relevant to their treatment-seeking process, one such
qualitative study explored motivations for seeking treat-
ment among a broad array of substance users [18]. Such
motivations included dissatisfaction with oneself, influences
of friends, family, and spiritual interventions. As one sys-
tematic literature review accentuated, the majority of the
research on individuals’ reasons for entering substance mis-
use treatment has been quantitative, which regrettably
deemphasizes the patient’s perspective [19]. As such, the
use of qualitative methodology is recommended for extend-
ing such understanding [19]. The current study explores
consumer perspectives of the MAT-seeking experience
using qualitative methodology.
Understanding treatment seeking from the consumer
perspective has implications for policy. For instance,
restrictive federally imposed limits on the number of
buprenorphine patients a provider can treat may serve
as a barrier for receiving services [15], particularly in
communities with limited provider availability. With all
of this in mind, there remains a need to understand the
subjective treatment-seeking process of consumers with
self-identified opioid use disorder who would benefit
from MAT. Such an understanding can help policy
leaders and interventionists make decisions that facili-
tate, rather than stymie, individual treatment seeking in
addition to illustrating how existing policies and proto-
cols affect the lives of consumers.
Method
This research was based on a larger mixed-methods
study that explored how both treatment providers and
potential treatment consumers understand MAT. The
aim of the current project was to explore what factors
influenced Alaskan MAT consumers (including those
who sought or considered using MAT) treatment-
seeking process.
Community involvement and ethical considerations
The study was conducted in Fairbanks, a city of about
32,000 people in the Interior region of Alaska [20]. Al-
though this population meets criteria for an urban area
according to the United States Census Bureau [21], the
Fairbanks and Interior region has many qualities of rural
life (e.g., higher rates of substance abuse, limited access
to health care, travel barriers, and stigma associated with
behavioral health services) [22]. This project utilized
community-based participatory research principles in-
cluding shared ownership, community analysis of social
problems, a strength-based and collaborative approach,
a focus on action, and an iterative process [23, 24]. As
such, it operated under the guidance of Turning Point
Counseling Services (a local private counseling and sub-
stance abuse center), the Alaska Advisory Board on Al-
coholism and Drug Abuse, stakeholders in the
community, and MAT professionals. It was approved by
the University of Alaska Fairbanks Institutional Review
Board (523384–9) and funded by the Alaska Mental
Health Trust Authority.
Participants
The study sample included people 18 years or older liv-
ing in Alaska who: (1) met criteria for an opioid use dis-
order at some point in their life, and (2) had been
impacted by medication-assisted service delivery (e.g.,
received services, been denied of services, encountered
barriers to obtaining services, or avoided seeking ser-
vices). Exclusion criteria included individuals that were
actively suicidal, experiencing psychosis, or who directly
Hewell et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:3 Page 2 of 10
received services from the researchers who collected
data.
Focus groups and semi-structured interviews explored
participants’ perceptions relevant to MAT. There were a
total of 11 participants; the majority were female (64%,
n = 7). Nine participants had received MAT at some
point in their lives, seven had been or were currently in
a methadone treatment program, and two had been in a
buprenorphine treatment program.
The first focus group was conducted with four patients
who were currently engaged in MAT. Subsequently,
three interviews were conducted with individuals who
were opioid-free at the time of the interview. Finally, a
second focus group, which included four individuals in
recovery who were receiving support from a mutual self-
help group, was conducted. All study participants had
considered using buprenorphine treatment at some
point in their recovery.
Procedure
Recruitment strategies included word-of-mouth, flyer, and
networking techniques. Individuals who participated in
the study were asked if they knew others who might be in-
terested in participating. This snowball sampling proced-
ure was utilized to build relationships, trust, and gain
entry into the community. Individuals were screened for
study criteria and, after obtaining written informed con-
sent, all interviews and focus groups were audio-recorded.
Upon completion of data collection, participants were
screened for distress, debriefed, thanked, and compen-
sated with $30 gift certificates.
Participants were queried about the following: (1) experi-
ences seeking treatment including barriers to entering and
remaining in treatment (e.g., “Some people report that they
had a hard time receiving medication-assisted services for a
number of reasons. When you were seeking treatment, did
you experience any barriers?”) (2) treatment preferences
(e.g., “what would the ideal program consist of?”), (3) suc-
cess in MAT (e.g., “What successes have you experienced
after engaging in medication-assisted treatment?”), and (4)
beliefs about the cause of addiction (e.g., “What are the
most important factors that contribute to your addiction?”).
Participants were also asked about perceptions and atti-
tudes related to MAT for themselves and for others (e.g.,
“What do you think about buprenorphine?”, and “What at-
titudes do you think community members have toward
Medication-assisted treatment?”).
Following the grounded theory techniques of theoret-
ical sampling [25], data collection was informed by par-
ticipant responses. After each interview or focus group
was conducted, researchers discussed impressions, which
informed subsequent prompts. After each phase of data
collection, raw data in the form of interview and focus
group audio recordings was transcribed and input into
Nvivo10 software.
Data analysis
Using grounded theory, data were coded using open,
axial, and selective coding techniques [25]. The re-
searchers evaluated their biases and mitigated these by
consulting with an expert in qualitative analysis that had
limited knowledge of opioid use disorders.
The first two authors collectively coded each transcript
into the major content domains, developed an initial
codebook for each domain, and began to code the do-
mains using the initial codebook. After agreeing on the
dependability of the codebook, they independently coded
the domains and routinely checked for agreement. Dis-
crepancies were collaboratively discussed. These strat-
egies served to enhance reliability and protect against
coder drift.
Results
The conceptual model emerging from the analyses illus-
trates an overarching meta-theme (individual and systemic
factors) as well as domains that influenced the treatment-
seeking process (see: Fig. 1). The model is best described as
a highway with on-ramps and exits that can keep individ-
uals on a path of opioid misuse or facilitate treatment seek-
ing, which ultimately leads to the road to recovery.
Individual and systemic factors
Participant stories highlighted the role of individual and
systemic factors, which contextually frame the treatment-
Fig. 1 Treatment-seeking road
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seeking road as a meta-theme. These factors influenced an
individual being able to enter, or having to exit from, their
treatment-seeking road along the three domains (de-
scribed below).
Individual factors included intrinsic attitudes, beliefs,
values, and motivations in seeking and completing treat-
ment. Systemic factors included broader social support,
family, treatment, public policy, and culture. The indi-
vidual and systemic influences interacted bidirectionally
along each individual’s unique treatment-seeking road.
For instance, one participant recalled, “once I started go-
ing and hearing from others, hearing what the program
means, going to meetings, I started experiencing
strength and hope…I wanted what they had…I’m sick
and tired of being sick and tired.” In this example, the
participant had internal factors (being “sick and tired of
being sick and tired”) that interacted with external influ-
ences (supportive others engaged in treatment), and in-
fluenced their treatment-seeking road through social
learning (“experiencing strength and hope”). This meta-
theme is present throughout the three key domains as
they relate to the consumer’s experience before and dur-
ing treatment, and in recovery.
Key domains
While the meta-theme encompasses broad elements
framing participants’ experiences, three key domains
represent qualities that affected how participants navi-
gated their treatment-seeking road, including: (a) models
of addiction and MAT, (b) barriers and facilitators, and,
(c) the road to recovery. Models of addiction and MAT
included implicit factors that inform the participants’
treatment-seeking process. Facilitators and barriers in-
cluded experiences that made it easier or harder to ob-
tain treatment. All of these constructs shaped the
participants’ road to recovery, which was primarily de-
scribed as a process that happens later in, or after,
treatment.
This process is represented as a road in Fig. 1 to illus-
trate the progressive nature of treatment-seeking. How-
ever, just like merging lanes on a highway, degrees of
overlap along the treatment-seeking road exist. For in-
stance, participants might describe barriers that are
based in models of addiction and MAT, or they might
describe facilitators that influence their road to recovery.
Models of addiction and MAT
Participants shared their lived experiences, beliefs, and
understandings related to addiction and MAT, which
established internal models. These models operated as
inherent frameworks that influenced their treatment-
seeking process. Specifically, participants described how
they understood or explained the cause of addiction, be-
liefs about getting clean, and the withdrawal process.
One participant highlighted the individual and systemic
influences involved in his understanding of addiction:
For me there are both individual and social factors.
Individually… genetically, I come from a long line of
people who are addicted to substances. Socially,
culturally, (substance abuse in) my neighborhood
where I grew up was culturally appropriate. A man
drank; got loaded; it was actually a rite of passage.
And I think after that particular point, it kind of woke
up the dragon biologically and almost created a
downward spiral in a lot of scenarios. Physically,
emotionally, and the fact that I came from an area
that I guess you could say struggled. The whole
community struggled with addiction so it was kind of
like this acceptance of everybody kind of like abus(ing).
That was a contributing factor. It was a way of coping
with things—to medicate with substances.
Explanatory models of addiction such as the example
above informed participants’ beliefs about getting clean.
For instance, believing that addiction is caused by bio-
logical and contextual factors may lead someone to be-
lieve that biological and social components must be
addressed in order to recover (e.g., by reducing physio-
logical cravings and building social support for recov-
ery). These explanatory models had implications for
treatment, as many participants in this study believed re-
covery was a lifelong process.
Additionally, withdrawal was described as a difficult as-
pect of addiction that sometimes led people to go back to
misusing opioids. As this participant illustrated: “(With-
drawal) was physical, mental, emotional, spiritual. I was a
disaster for like…I think I made it…four days, and then I
went back.” Participants reported withdrawal made it chal-
lenging to quit or stay off opioids without support. As one
participant noted, “So I had to come off of it cold turkey,
and it was a terrible, terrible experience, so I just went back
to heroin.” As such, participants described MAT as being
helpful in decreasing withdrawal symptoms, which allowed
it to be used as a “stepping stone” to recovery.
In addition to their models of addiction, participants
discussed their models of MAT. This included percep-
tions of how others feel about MAT, and participants’
own implicit beliefs about MAT. Participants primarily
perceived others as having negative views, including
stigma and judgment, about MAT. Negative societal
views, including the belief that people on MAT were still
addicts and not in the recovery process, interfered with
participants’ progress along the treatment-seeking road.
Participants believed that these views were communi-
cated overtly (e.g., transmitted through the media) and
covertly (e.g., through misassumptions acquaintances
had). For example, one participant stated:
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I hear it all the time: ‘you’re not sober’. And it really
hurts my feelings because I worked hard…from where I
was to where I (am) now…I got my own place, I got my
disability, I got everything on track. And all she said
was, ‘you’re still not sober’.
Nevertheless, participants had varying personal beliefs
about MAT, including believing it was a good aid in the
recovery process, thinking it was trading one drug for
another, and having negative emotions associated with
MAT. For instance, one participant stated:
Looking back on it, (buprenorphine) was my miracle
drug because I know I couldn’t do it without that.
That first three months was so painful, I felt I was
being ripped apart by wolves, the cravings were so
intense.
However, another noted, “I guess I felt like, looking
back on that, I feel like I put like a Band-Aid® on my
gunshot wound.” Regardless of whether individuals felt
that MAT was beneficial or detrimental, all participants
discussed feeling that MAT alone was not enough and
should be paired with support or treatment. In terms of
recovery, one participant noted the importance of an in-
tegrated buprenorphine program:
It took me a long time to realize how important
[buprenorphine] was to my recovery—it was that
stepping stone from before and after. I wouldn’t be
[here] if it wasn’t for the in-between with the […]
program.
Facilitators and barriers to seeking treatment
Participants discussed four facilitators and barriers in-
cluding attitudes, support (or the lack thereof ) in treat-
ment, resources, and the structure and context of
treatment. These facilitators and barriers shaped partici-
pants’ attempts to seek MAT.
Attitudes Certain attitudes, including social and inter-
nalized stigma (for utilizing MAT) that were affected by
societal values, and a personal decision to change
emerged from participants’ stories as being relevant to
their ability to enter treatment. These attitudes, which
served as facilitators or barriers to treatment, were ne-
cessarily influenced by the implicit models discussed
above. Social stigma, including negative public beliefs
about addiction, presented a roadblock to seeking MAT
by affecting receptivity to treatment. One participant
noted:
“People are like, ‘drug addicts are evil. Evil junkies,
evil!’ So I don't even think people are really educated
on drugs, much less treatments or [buprenorphine]…
that is where every goes wrong…because most people
don’t want to get help or talk about it cause you’re
[assumed to be] evil.”
This example depicts how societal stigma stems from
a lack of health literacy about MAT. This societal stigma
can stymie consumers’ reaching out and getting into
MAT, even if they believe it is effective.
Participants highlighted the need to change negative at-
titudes about addiction, substance abuse treatment, and
MAT on a systemic level. One participant suggested, “cre-
ating a culture that is conducive and attractive for people
in recovery for all different manifestations of recovery
whether it’s medically-assisted or abstinence, whatever.”
Relatedly, values that spur from our “Puritan Society”
could contribute to societal or internalized stigma. Soci-
etal stigma, such as the belief that those who have an ad-
dictive disorder have a poor character or the de-
emphasis on the biological contributions on addiction,
were described as barriers to seeing MAT as an accept-
able option for some. Additionally, an individual’s cul-
ture (e.g., ethnicity, socio-economic background, social
ecological history) influenced his or her treatment-
seeking experience. One participant stated:
I think being Alaska Native and having addiction and
trying to get help, there’s a huge stigma to that. It’s
kind of like, you’re a shame. It’s like very shameful.
We’re very prideful people, you know? It’s a lot harder
for people to get clean.
This example accentuates the importance of consider-
ing how an individual’s cultural context impacts the so-
cietal stigma they face and the obstacles they encounter
in seeking treatment. It also illustrates how societal
stigma may be internalized, thereby effecting consumers’
feelings about themselves as they try to access treatment,
including the experience of shame.
While social and internalized stigma could make it
difficult to seek treatment, personal decision to change
accelerated participant progress along the treatment-
seeking road. For instance, one participant noted, “you
have to want it,” and another accentuated that staying
clean was the most important thing in his life: “I want it
more than anything. Stay clean first. That’s about it. I
have nothing without it.”
Support Some participants believed their therapists’
support, unconditional positive regard, and collabora-
tive treatment environment are what got them through
treatment challenges. One participant discussed the
role of a compassionate and collaborative treatment en-
vironment: “What I’ve seen be very successful is just
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compassion and like, ‘let’s do this. Like let’s figure it out
together.’”
Others felt that treatment was nontherapeutic and un-
glamorous, and that providers were unhelpful, “jaded”,
and/or lacked health literacy, which presented significant
barriers to seeking and staying in treatment. Likewise,
another participant discussed how stigma and the lack
of support in the treatment environment could nega-
tively impact recovery: “Well, I guess if you’re on [bupre-
norphine] and you go to meetings and you just hear
whisperings and there was stigma …You don't want to
go to a meeting where it’s not unconditional love.”
Support and connection across different systems (e.g., so-
cial, familial) was also described as a contributing factor in
addiction, treatment seeking, and recovery. One participant
noted:
When you’re using, you have a tribe. When in recovery
and I go to NA, I have a tribe. When I relapsed, what
made me do that was I betrayed my using tribe…
People are necessary for recovery. It’s necessary for me.
Connection. That’s it…it’s saving my life.
This powerful quote illustrates how support and con-
nection affect the entire treatment-seeking process, from
addiction to relapse to recovery. Clearly, support and
connection have an important role in why participants
do or do not seek MAT.
Resources The lack of resources, including health liter-
acy, access/availability, and financial resources, were pri-
marily discussed as barriers to MAT. For instance, one
participant highlighted the detrimental influence of lim-
ited treatment availability:
“there’s a very narrow window of opportunity in
somebody’s addiction to get in (treatment) so when
they finally decide, okay I think I need something, and
then there’s nothing available, then that window has
passed and you have to wait for the next one.”
This acute description demonstrates the need for avail-
ability and swift action on the part of treatment facilities.
Additionally, finances served as a barrier for many as il-
lustrated by this participant: “I think the financial aspect
is one of people’s biggest fears. Because they don’t have
money. And even the willingness to make payment plans
is more incentive for people to get help.” As a result of
the lack of treatment availability and financial barriers,
many participants were left feeling hopeless and getting
high, having to travel long distances in dangerous cir-
cumstances to seek treatment, or committing a crime to
go to jail to “get clean.”
Finally, participants attributed stigma and misassump-
tions about MAT to a lack of health literacy: “There’s no
knowledge about it, people just don’t understand it. And
they’re not going to unless they’re told.” Nevertheless, our
analysis revealed that education alone is not enough. One
participant stated, “Education may not always be the an-
swer…I do believe information, education…those are things
that for all providers might be helpful; not so much if the
person presenting it has their own biases.” In other words,
it is important to increase health literacy while also address-
ing implicit and systemic stigma about MAT. Undoubtedly,
access to both physical and informational resources are im-
portant for progression along the treatment-seeking road.
Treatment structure In regards to treatment structure,
participants discussed a strict treatment structure as benefi-
cial in the beginning of treatment, while noting that more
autonomous functioning can facilitate recovery later in
treatment. In this way, some participants implied that MAT
could itself become a source of oppression and restriction
that kept them locked in through an “umbilical cord”. Al-
ternatively, MAT that offered more freedom and flexibility,
especially when the consumer was stable, was described as
having the ability to foster strength. As this participant
noted: “I honestly, first time in my life, took it like I was
supposed to. Took it like the bottle told me to. And it was
kind of a liberating experience. To be in control and in pos-
session of something like that.” This speaks to the import-
ance of matching the treatment structure with where
consumers are developmentally.
Overall, the various treatment facilitators and barriers
interacted with each other to influence the road to re-
covery. For example, barriers such as stigma and access
to care were especially difficult to overcome for con-
sumers with less support (e.g., family, recovery tribe).
On the other hand, motivation to change was a primary
source of strength, inspiring individuals to seek treat-
ment even in the face of barriers.
Road to recovery
In addition to models of addiction and MAT and barriers
and facilitators, participants discussed their experiences
and expectancies later in treatment, or their road to re-
covery. This included reaching a critical mass point, in-
ternal factors (e.g., taking personal responsibility),
contextual factors (e.g., having connection and support),
and living a program of recovery (e.g., having investment
in the process).
Reaching a “critical mass point” was key in participants’
transition toward recovery. This was characterized as dra-
matic moments that prompted participants to change in-
cluding having a relapse, hitting rock bottom, perceiving
that they had a choice to make changes, “being sick and
tired of being sick and tired”, and realizing that misusing
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opioids was no longer an effective coping mechanism. After
the critical mass point was reached, both internal and exter-
nal factors helped people move toward recovery.
Internal factors seen as necessary to longer-term “re-
covery” included will, dedication, clarity of values, and
spirituality. These factors were often described as influ-
ential in helping participants overcome adversity. In the
following example, will and clarity of values helped an
individual persist through difficult situations to remain
in the living program of recovery after treatment:
I think there are people who are strong enough to get
through (the stigma). I probably wouldn’t give a shit, I
want to get clean you know? I know what I want. But
other people are not like that. They’re not that strong
willed or minded.
In addition to will, motivation and believing in oneself
were described as important. For instance, one partici-
pant stated, “I feel like you can’t push somebody. You
got to come to it on your own.” Another participant
pointed out, “You have to change. That was a huge
epiphany for me: that I’m the problem.”
External factors (e.g., a supportive clinician, positive
treatment structure, social learning through peers)
helped participants continue moving forward on their
road to recovery. One participant described how her
dedication to her family kept her “sober”:
Every time I would think of feeling like I wanted to use
again, I would just think about losing [my kids]. I
would never, ever want to lose them or leave them or
do anything—and it’s a big one for me. It’s kept me
sober for the last 4 years.
Even so, participants did not discuss recovery as a
permanent point, but they believed it was important
to have a living program of recovery. They generally
believed this living program of recovery was an indi-
vidualized process that is different for every person,
but likely included an investment to themselves to
stick to treatment, changes in thought processes, using
MAT as a stepping-stone toward recovery, and going
through a process of change that was not a “quick fix.”
Participants discussed the progress they had made,
and many were able to look back and notice how they
progressed. For instance, one participant recalled, “If
you really do look at everybody in here and where they
were compared to where they are now, like most of us
have gotten back on track, we all have our kids, gone
back to school.” Continuing to progress was also a
component of the living program of recovery. As this
person noted, “I can’t stop. It never stops, the disease
doesn’t go away.”
Discussion
The current study is one of the few studies to examine the
attitudes and perceptions of consumers who may benefit
from the MAT, buprenorphine. It illustrates the individual
and systemic factors that affect the treatment-seeking
process and elucidates the importance of contextual fac-
tors, such as stigma, access to resources, and support.
Ecological systems theory [26] provides a useful frame-
work for conceptualizing this study’s findings. It posits
that each individual exists within a nest of systems that
contextualizes and influences individuals’ behaviors [26].
In our study, each person’s addiction, treatment-
seeking process, and recovery can be framed within the
nested systems. These systems include macrosystem
(e.g., cultural norms, protestant values, abstinence-only
orientation), exosystem (e.g., mass media as a source of
stigma, public policy), mesosystem (e.g., insurance, com-
munication between providers), microsystem (e.g., con-
sequences of drug use on family, employment, social
supports), and individual (e.g., motivation to change,
willpower).
The important role ecological factors play in the devel-
opment, maintenance, and treatment of substance abuse
is well established [27] and is also considered in the Na-
tional Institute of Drug Abuse’s [NIDA] principles of ef-
fective treatment [28], which includes consideration of
treatment and biopsychosocial individual factors. Results
from the present study expand upon NIDA’s principles
for effective treatment by considering broader ecological
influences including societal attitudes, cultural norms,
access to resources, and policy that influences how treat-
ment is delivered.
The role individual and systemic factors play in MAT
seeking found in this study corroborates with the con-
struct of recovery capital [29–31]. The construct of re-
covery capital proposes that the accumulation of internal
and external resources affect one’s ability to recover
from addiction. It is suggested that professionals work-
ing with people in treatment for addiction can facilitate
recovery on three levels of recovery capital: personal re-
covery capital, family/social recovery capital, and com-
munity recovery capital [31]. This study’s findings
demonstrate similar constructs are relevant to MAT
seeking while revealing the interactional relationship of
these resources.
For example, macrosystem, exosystem, and mesosystem
(e.g., cultural assumptions, policy and funding) influences
frequently served as barriers, whereas participants’ indi-
vidual and microsystem resources (e.g., motivation to
change, having support from family and treatment pro-
grams) more frequently served as facilitators to treatment
and recovery. As such, policy makers might take these
findings into consideration by creating policy and allocat-
ing funds that support microsystems from the bottom-up,
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rather than dictating the operation of treatment from the
top-down. This may include providing funding for rural
areas or in areas that are affected by opioid misuse, or
allowing treatment programs to decide their own treat-
ment operations (including the number of patients a pro-
vider can serve) as opposed to having to meet a federally
imposed standard. Also, treatment practitioners may want
to focus on individual strengths that can serve as personal
resources for recovery.
Importantly, the source of power affecting MAT seek-
ing could originate in any system and could change
overtime. For instance, someone may originally seek
MAT because of their children (microsystem level influ-
ence) yet remain in treatment because of their children
and their own individual motivation (microsystem and
individual level influences). Likewise, practitioners
should keep in mind that the source and degree of mo-
tivation fluctuate, and refine interventions accordingly,
flexibly drawing on shifting sources of recovery capital.
Participants in our study discussed willpower, believing
in one’s ability to change, and motivation to change as
individual factors important for seeking treatment and
maintaining recovery. Similarly, self-efficacy [32–34], de-
fined as confidence in one’s ability to do something (e.g.,
be abstinent or not use), and perceived locus of control
[35], defined as the belief that change is within one’s
power, play important roles in overcoming substance use
disorders. Participants viewed buprenorphine as a tool
for gaining such control – a stepping-stone to recovery.
This is consistent with Miller and Rollnick’s [36] work
positing that three conditions are necessary for change:
being ready, willing, and able. For some participants,
MAT was a tool in their process of cultivating readiness
(helped them prioritize and feel capable of quitting),
willingness (helped them believe that change is import-
ant), and ability (helped them manage withdrawal symp-
toms, which built confidence and investment to change).
In this study, specific individual factors, including self-
efficacy and motivation to change, facilitate MAT seek-
ing. Thus, interventionists should target their efforts
with self-efficacy and motivation to change in mind. Per-
haps a practitioner could work to increase self-efficacy
by taking a strength-based approach and cater treatment
to the consumer’s motivation to change by using a mo-
tivational interviewing approach. Additionally, a com-
munity psychologist could emphasize these individual
strengths when developing community interventions.
Participants in this study also emphasized the importance
of contextual factors in treatment-seeking decisions, includ-
ing support from family, others in treatment, treatment
providers, and the broader community and context. Family
history and social support are recognized as important ex-
ternal factors that affect addiction and treatment [35]. In
one study with people with opioid use disorders, a lower
quality of social support related to higher perceived stress,
which in turn was associated with greater opioid misuse
[37]. While the negative consequences of poor social sup-
port was mentioned by our participants, they primarily em-
phasized positive aspects of social interactions, including
the way compassion and positive social support facilitated
their treatment-seeking process.
Because some factors of the community and cultural
context could serve as facilitators or barriers, it is im-
portant for interventionists to take this into account
when working with people in MAT. For instance, thera-
pists should consider the individual in their cultural con-
text. Additionally, societal stigma should be addressed
by considering the cultural context in which it is nested.
Health literacy and the treatment environment also in-
fluenced participants’ ability to get what they needed out
of treatment. Many participants described being “unin-
formed” when seeking treatment. While health literacy
can combat some barriers, societal stigma must also be
addressed by challenging attitudes. Thus macrosystem
interventions should inform those who would benefit
from MAT about treatment options and educate people
globally about MAT to challenge attitudes and fight so-
cietal stigma.
While MAT facilitated recovery for some participants,
it was also described as a barrier to furthering recovery
when consumers felt trapped in the system. This corre-
sponds with findings from a previous qualitative study
where participants described methadone as “liquid hand-
cuffs” that prevented them from actualizing recovery
[38]. Thankfully, a supportive and collaborative therapist
and treatment structure were described as significant fa-
cilitators to staying in treatment and maintaining recov-
ery. Similarly, the therapeutic alliance, which is patient-
therapist agreement on goals, task, and the bond [39]
has been shown to improve outcomes for those with
opioid dependence [40]. Thus, providers and treatment
facilities should cultivate a supportive treatment envir-
onment and encourage consumer autonomy.
Finally, there are unique challenges that rural citizens face
due to distinctive cultural and geographical context, includ-
ing higher rates of substance abuse, limited access to health
care, travel barriers, and stigma associated with behavioral
health services [22]. The participants of this study accentu-
ated the geographical and availability barriers in Alaska.
Even when participants are motivated to change, long wait-
ing lists and limited treatment availability can close a valu-
able window of opportunity. In rural settings with limited
providers and geographical challenges that make it difficult
to obtain treatment elsewhere, federally imposed caps on
patient limits [15] for buprenorphine providers can be seen
as an even bigger barrier to treatment. Policy makers may
consider advocating for making exceptions to the provider
limit on patients, particularly in rural areas.
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These barriers to access have significant practical im-
plications for society because, while substance abuse
may commonly be assumed to be an individual disease,
its social impacts on health and judicial systems exceed
$510 billion annually [2]. MAT is only accessible to a
limited number of individuals who would benefit from
treatment [2], and contextual factors (including socio-
economic status and rural location) affect treatment ac-
cess [22].
Strengths, limitations, and future directions
A major limitation of this study is that it included a small
sample. While we used snowball-sampling procedures to
attempt to reach a broad range of those who would bene-
fit from MAT, most participants were aware of some treat-
ment services, and we were limited in our ability to reach
individuals who do not access treatment services. Thus,
this convenience sample may not be representative of
those who are very limited in resources. The limited sam-
ple warrants caution for generalizing results. Additionally,
our model is derived from a sample that has contextual
factors that may not generalize directly to other commu-
nities. Therefore, specific influences that affect MAT treat-
ment seeking may vary. Future research exploring MAT
treatment seeking in underserved communities should at-
tempt to obtain larger, diverse and representative samples
of those who would benefit from MAT.
However, like another qualitative study [41], the sample
size was sufficient for illuminating consumers’ central
themes and concerns related to the research questions of
this study, and therefore reaching data saturation. Add-
itionally, our study provides an in-depth perspective of
MAT treatment seeking, using participants’ own words to
illustrate their struggles and successes, and offering treat-
ment providers and policy makers insight regarding par-
ticipants’ lived experiences through their own eyes [42]. It
integrates a community-based approach in a real-world
setting, which increases validity through drawing on com-
munity expertise, builds empowerment, and facilitates the
utilization of findings [43–45].
While research has explored attitudes towards metha-
done, this is one of the few studies to qualitatively exam-
ine the perceptions of those who would benefit from
buprenorphine treatment. Although this treatment has
demonstrated efficacy [9–14], the full potential of services
cannot be actualized unless the consumer is at the fore-
front of treatment. Moreover, these consumers’ perspec-
tives may inform considerations for buprenorphine policy.
Future research can extend on the current project by in-
vestigating the difference between methadone and bupre-
norphine in facilitating recovery, the meaning of success
in buprenorphine treatment, and the role of systemic bar-
riers, including funding and systemic support of bupre-
norphine MAT.
Conclusion
The current study highlights that addressing the interre-
lated individual and contextual factors affecting treatment-
seeking is critical. Further, there are discrepancies between
what is needed for optimal progress on treatment-seeking
road and the political and contextual barriers consumers
may face in obtaining timely treatment that addresses their
needs. As such, interventionists should recognize individual
strengths while prioritizing the cultural milieu when advis-
ing clinical and community change efforts to improve the
delivery of MAT and buprenorphine services. In doing so,
health literacy, compassion, and understanding should be
increased and disseminated across the different systems
(i.e., policy makers, general public, frontline service delivery
professionals, consumers) while combatting negative and
misinformed beliefs that perpetuate stigma. Finally, our
findings echo that it is important to increase access to
MAT programs that integrate medication with psychosocial
components in substance use disorder treatment [13, 46].
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